TY - JOUR
T1 - Multicenter study of the safety and effects of magnetic resonance imaging in patients with coronary sinus left ventricular pacing leads
AU - Sheldon, Seth H.
AU - Bunch, T. Jared
AU - Cogert, Gregory A.
AU - Acker, Nancy G.
AU - Dalzell, Connie M.
AU - Higgins, John V.
AU - Espinosa, Raul E.
AU - Asirvatham, Samuel J.
AU - Cha, Yong Mei
AU - Felmlee, Joel P.
AU - Watson, Robert E.
AU - Anderson, Jeffrey L.
AU - Brooks, Miriam H.
AU - Osborn, Jeffrey S.
AU - Friedman, Paul A.
N1 - Funding Information:
Dr. Bunch has served on a Boston Scientific advisory panel. Dr. Cogert has served on the Speakers Bureau for Pfizer/BMS for Eliquis and for Zoll for Lifevest; consults for defibrillators for Medtronic; and provides fellows education for cryoballoon for Medtronic. Dr. Asirvatham has consulted for Abiomed, Atricure, Biotronik, Biosense Webster, Boston Scientific, Medtronic, Spectranetics, St. Jude Medical, Sanofi-Aventis, Wolters Kluwer, and Elsevier. Dr. Friedman has consulted for Bard Electrophysiology, Biotronik, Leadexx, Sorin Medical, and Boston Scientific; and has received research grants from Medtronic and Biotronik.
Publisher Copyright:
© 2015 Published by Elsevier Inc.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background Magnetic resonance imaging (MRI) in patients with left ventricular (LV) leads may cause tissue or lead heating, dislodgment, venous damage, or lead dysfunction. Objective The purpose of this study was to determine the safety of MRI in patients with LV pacing leads. Methods Prospective data on patients with coronary sinus LV leads undergoing clinically indicated MRI at 3 institutions were collected. Patients were not pacemaker-dependent. Scans were performed under pacing nurse, technician, radiologist, and physicist supervision using continuous vital sign, pulse oximetry, and ECG monitoring and a 1.5-T scanner with specific absorption rate <1.5 W/kg. Devices were interrogated pre- and post-MRI, programmed to asynchronous or inhibition mode with tachyarrhythmia therapies off (if present), and reprogrammed to their original settings post-MRI. Results MRI scans (n = 42) were performed in 40 patients with non-MRI conditional LV leads between 2005 and 2013 (mean age 67 ± 9 years, n = 16 [40%] women, median lead implant duration 740 days with interquartile range 125-1173 days). MRIs were performed on the head/neck/spine (n = 35 [83%]), lower extremities (n = 4 [10%]), chest (n = 2 [5%]), and abdomen (n = 1 [2%]). There were no overall differences in pre- and post-MRI interrogation LV lead sensing (12.4 ± 6.2 mV vs 12.9 ± 6.7 mV, P =.38), impedance (724 ± 294 Ω vs 718 ± 312 Ω, P =.67), or threshold (1.4 ± 1.1 V vs 1.4 ± 1.0 V, P =.91). No individual LV lead changes required intervention. Conclusion MRI scanning was performed safely in non-pacemaker-dependent patients with coronary sinus LV leads who were carefully monitored during imaging without clinically significant adverse effect on LV lead function.
AB - Background Magnetic resonance imaging (MRI) in patients with left ventricular (LV) leads may cause tissue or lead heating, dislodgment, venous damage, or lead dysfunction. Objective The purpose of this study was to determine the safety of MRI in patients with LV pacing leads. Methods Prospective data on patients with coronary sinus LV leads undergoing clinically indicated MRI at 3 institutions were collected. Patients were not pacemaker-dependent. Scans were performed under pacing nurse, technician, radiologist, and physicist supervision using continuous vital sign, pulse oximetry, and ECG monitoring and a 1.5-T scanner with specific absorption rate <1.5 W/kg. Devices were interrogated pre- and post-MRI, programmed to asynchronous or inhibition mode with tachyarrhythmia therapies off (if present), and reprogrammed to their original settings post-MRI. Results MRI scans (n = 42) were performed in 40 patients with non-MRI conditional LV leads between 2005 and 2013 (mean age 67 ± 9 years, n = 16 [40%] women, median lead implant duration 740 days with interquartile range 125-1173 days). MRIs were performed on the head/neck/spine (n = 35 [83%]), lower extremities (n = 4 [10%]), chest (n = 2 [5%]), and abdomen (n = 1 [2%]). There were no overall differences in pre- and post-MRI interrogation LV lead sensing (12.4 ± 6.2 mV vs 12.9 ± 6.7 mV, P =.38), impedance (724 ± 294 Ω vs 718 ± 312 Ω, P =.67), or threshold (1.4 ± 1.1 V vs 1.4 ± 1.0 V, P =.91). No individual LV lead changes required intervention. Conclusion MRI scanning was performed safely in non-pacemaker-dependent patients with coronary sinus LV leads who were carefully monitored during imaging without clinically significant adverse effect on LV lead function.
KW - Cardiacimplantable electronic device
KW - Cardiacresynchronizationdevice
KW - Coronary sinus
KW - Implantablecardioverter-defibrillator
KW - Magnetic resonanceimaging
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84921044573&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921044573&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2014.11.037
DO - 10.1016/j.hrthm.2014.11.037
M3 - Article
C2 - 25433144
AN - SCOPUS:84921044573
SN - 1547-5271
VL - 12
SP - 345
EP - 349
JO - Heart Rhythm
JF - Heart Rhythm
IS - 2
ER -